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NUT midline carcinoma of the larynx: an international series and review of the literature
Aims: NUT midline carcinoma (NMC) is a rare undif-
ferentiated and aggressive carcinoma that locates
characteristically to the midline of the head and neck,
and mediastinum. NMC is characterized by chromoso-
mal rearrangements of the gene NUT, at 15q14. The
BRD4 gene on 19q13 is the most common transloca-
tion partner forming a fusion oncogene, BRD4–NUT.
By the end of 2014, the International NUT Midline
Carcinoma Registry had 48 patients treated for NMC.
Laryngeal NMC are exceedingly rare, and we report a
case series of seven cases.
Methods and results: We searched for cases in files of
different hospitals as well as a thorough search of the
English language literature. The diagnosis of NMC is
made by demonstration of NUT rearrangement either
by immunohistochemistry, fluorescence in-situ
hybridization (FISH) or reverse transcription–poly-
merase chain reaction (RT–PCR). We found three
previously published cases, and in this series add four
cases of our own.
Conclusions: NMC consists of monomorphic, often
discohesive, cells with an epithelioid appearance and
distinct nucleoli. The tumours typically show abrupt
squamous differentiation. The mean age of the
patients was 34 years, hence significantly lower than
that for conventional laryngeal carcinoma. All
tumours were located in the supraglottis and five
patients died of the disease after 3, 7, 8, 9 and
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11 months. Laryngeal NMC may be underdiagnosed,
and an increased awareness among pathologists is
warranted. NMC has characteristic morphological fea-
tures, and positive immunostaining with the NUT
antibody is diagnostic. Its aggressive behaviour
demands a very intense treatment strategy and the
need for its recognition is emphasized further by new
promising treatment strategies.
Keywords: BRD4, larynx, NUT, NUT midline carcinoma, t(15;19), undifferentiated carcinoma
Introduction
Nuclear protein in testis (NUT) midline carcinoma
(NMC) is a rare aggressive cancer of which exceed-
ingly few laryngeal cases have been reported.
Although NMC is an undifferentiated carcinoma it
almost invariably shows features of squamous cell dif-
ferentiation and is regarded by many as a subtype of
squamous cell carcinoma.1–6 NMC is characterized by
chromosomal rearrangements of the gene encoding
NUT at 15q14, also known as NUTM1 or Chr15or-
f55.1–7 The bromodomain containing 4 (BRD4) gene
on 19q13 is the most common (approximately 70%
of cases) translocation partner gene to NUT resulting
in the t(15;19)(q14;p13) karyotype.8 The fusion
forms a 6.4-kb fusion oncogene, BRD4–NUT. The
encoded oncoprotein BRD4–NUT contributes to car-
cinogenesis by blocking epithelial cell differentiation
and drives growth of the NMC cells.6–9 Although rec-
ognized only recently, a series of publications since
2001 have established the concept of NUT NMC as a
distinct entity.1–25
NUT NMC is a poorly differentiated carcinoma that
can arise in different organs, but characteristically
locates to the midline of head and neck, and medi-
astinum. Initially NMC was thought to be a child-
hood cancer, but later studies have shown that it
affects people of all ages and there is a slight female
predominance of 1.5:1.23 The histology ranges from
almost entirely undifferentiated carcinomas to carci-
nomas with focal or even prominent squamous differ-
entiation, and NMC is probably best regarded as a
distinctly aggressive subtype of SCC that has a unique
and defined genetic abnormality. By 2011 at least 28
cases of NUT NMCs had been reported. Fourteen of
the 28 cases had originated in the head and neck,
but only one of these in the larynx.18 A recent study,
however, reported a fivefold increase in the diagnosis
of head and neck NMC from 2011 to 2014, and as of
31 December 2014, the International NUT Midline
Carcinoma Registry had 48 patients treated for
NMC.23 Part of this increase is due very probably to
the availability of the new antibody specific for the
NUT protein,16 facilitating more widespread labora-
tory diagnoses. NUT protein expression is normally
exclusive to the testes, and its expression outside the
testes is diagnostic of NMC.16 The diagnosis of NMC
is made by demonstration of the NUT rearrangement
either by NUT immunohistochemistry (IHC), fluores-
cence in-situ hybridization (FISH) or reverse transcrip-
tion–polymerase chain reaction (RT–PCR) (or
cytogenetic analysis). In this study we describe the
clinicopathological features of seven cases of laryn-
geal NMC, the largest series to date, and emphasize
the importance of its recognition by the pathologist,
particularly as the patients need extremely intensive
treatment and also because new promising treatment
strategies are at the horizon.
Material and Methods
Due to its rarity, we made a thorough search of the
English language literature (Medline, Pubmed) for
any documented laryngeal NMC. We were aware of
three unpublished cases from the different hospitals of
the collaborating authors, but we also searched for
cases in the files of three other different hospital
departments by Snomed code T24000 and M codes
80203 (undifferentiated), 80103 [not otherwise speci-
fied (NOS)] and 80003 (malignancy NOS). Further-
more, in an attempt to obtain a very crude
understanding of the prevalence of laryngeal NMC
among laryngeal SCCs, the database (1996–2016) of
another hospital was searched. Here all cases of diag-
nosed laryngeal SCC (M80703) were recorded (of
which 100 random cases were reviewed histologi-
cally), and during the same time-period all laryngeal
cases M coded 80203, 80103 and 80003 were col-
lected (all of which were reviewed histologically).
Immunohistochemistry was performed in five cases
using the NUT (C52B1) rabbit monoclonal antibody
(mAb #3625) (Cell Signaling Technology, Inc., Bos-
ton, MA, USA). The immunohistochemical procedure
was performed strictly according the manufacturer’s
recommendation for paraffin-embedded tissue. This
antibody detects endogenous levels of total NUT pro-
tein and endogenous levels of the BRD4–NUT fusion
protein found in NUT NMC. In all four laboratories
human testis was used as positive control (post-meiotic
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spermatids express NUT at approximately the same
level as NMC). In case 7 we also used a case of thymic
NUT NMC, established previously by FISH and C52B1.
The C52B1 antibody has been shown to be 100%
specific and 87% sensitive for the diagnosis of NMC,
and thus a positive NUT immunostaining by itself is
diagnostic of NMC.16,26
FISH analysis was performed in four cases. Dual-
colour bring-together FISH assays for BRD4 and NUT
gene loci using homebrew probes were performed on
formalin-fixed, paraffin-embedded, 4-lm tissue sec-
tions, as described previously.7
Results
We found only three cases published in the English
language literature,13,15,25 and have added four new
cases of our own. There were four males and three
females varying in age from 5 to 78 years, with a
mean of 34 years. All seven cases were located in
supraglottis and hence none in the glottic or subglot-
tic region. Five patients died of the disease after 3, 7,
8, 9 and 11 months. One patient is currently under-
going treatment and survival data were not given in
one of the previously published cases. The initial his-
tological diagnosis in two cases was poorly differenti-
ated carcinoma, and the remaining cases
undifferentiated carcinoma, invasive basaloid squa-
mous cell carcinoma, high-grade malignant neo-
plasm, and in two cases NUT carcinoma (Table 1).
The diagnosis of NUT NMC in the three previously
published cases was based on FISH in two cases and
IHC in one. In the three new cases known to us and
initiating this study (cases 4–6), the diagnosis was
based on IHC (and supplemented by FISH in two of
the cases). The search for tumours M coded 80203,
80103 and 80003 in three other hospitals yielded 38
cases, seven of which had a morphology that could
be compatible with NUT NMC. All 38 cases were
stained with the C52B1 antibody, and in one of the
cases (one of the seven with NUT-compatible mor-
phology) the immunostaining was unequivocally pos-
itive (case 7; Table 1). IHC with the NUT antibody
was thus positive, with diffuse nuclear staining in five
of the cases (Figure 1B). In two cases (cases 2 and
5), FISH showed a reciprocal fusion at both NUT and
BRD4 (Figure 1C). The tumour cells were pancytok-
eratin-, p63- and p40-positive but negative for neu-
roendocrine, lymphocytic and melanocytic markers.
The retrospective search in one hospital (1996–
2016) yielded seven cases of undifferentiated laryn-
geal carcinoma compared to the approximately 400
cases of conventional SCC (none of the random 100
cases reviewed histologically showed any undifferenti-
ated areas). All seven patients with undifferentiated
carcinoma were deceased (at an age between 35 and
80 years), but we were unable to trace the cause of
death. For different reasons, no suitable tissue was
available in for IHC in any of the seven cases, thus
we could not demonstrate the existence of a single
case of laryngeal NUT NMC during the same time
that we saw 400 cases of conventional laryngeal
squamous cell carcinoma. This is in accordance with
previous observations where none of 438 head and
neck squamous cell carcinomas stained positively
with the C52B1 antibody,16 and emphasizes the rar-
ity of NUT NMC, both in the larynx as well as in the
head and neck as a whole.
In all cases the histology showed features of an
undifferentiated carcinoma consisting of monomor-
phic cells with round to oval nuclei and distinct
nucleoli. The cells were primarily medium-sized and
arranged in sheets of different sizes, and cells slightly
separated from each other by clear spaces. Many of
these relatively discohesive cells had an epithelioid
appearance. Typically, the tumours showed abrupt
squamous differentiation (Figures 1A,D). Necrosis and
high mitotic rate were other features of these
tumours.
Discussion
NMC is defined by rearrangement of the NUT gene.
The t(15:19) translocation is the most common rear-
rangement that places NUT in frame with BRD4, the
latter being a ubiquitously expressed transcriptional
activator that drives expression of the BRD4–NUT
fusion gene. The BRD4–NUT fusion was first
described in 2003 by French and co-workers.7 It has
been hypothesized that NMC utilizes a genetic short-
cut to the development of SCC, which normally takes
years and the accumulation of multiple mutational
hits to develop.1,27,28 BRD4–NUT forms enormous
contiguous stretches of active chromatin (0.1–
1.5 Mb) that have been termed ‘megadomains’,
enriched with BRD4–NUT and p300. Expression of at
least a subset of megadomain-containing genes is crit-
ical to the growth of the host NMC cell. For example,
the ability of BRD4–NUT to fill whole regulatory com-
partments for genes such as MYC is thought to be
one explanation of the extremely aggressive nature of
NMC.6,29 In support of this idea, it has been shown
that MYC is a key downstream target of BRD4–NUT,
and is necessary and sufficient for blockade of
© 2016 John Wiley & Sons Ltd, Histopathology, 70, 861–868.
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differentiation in NUT carcinomas.3 It is of further
interest that TP63, a p53 family member whose
oncogenic DN isoform is expressed in the majority of
NMCs, maps to a megadomain in all NMC cells
tested6 and is required for NMC cell viability
in vitro.19,30
In approximately 75% of NMCs NUT is fused to
BRD4, BRD3 or NSD32,5,7,9 but in the remaining
cases to an unknown partner gene; these latter
tumours are termed NUT variants. The commercially
available monoclonal antibody C52B1 will detect all
forms of NMC, including BRD4–NUT, BRD3–NUT,
NSD3–NUT and NUT variants.17 Recently a case of
hypopharyngeal NMC was reported that had a novel
three-way translocation t(9;15;19;q34;q13;p13.1).20
Five of the six cases presented here were positive for
the NUT antibody, while the BRD4–NUT fusion was
demonstrated by FISH in one case. Our extensive
review shows that primary laryngeal NMC is a rarity,
and has been underdiagnosed. It shares the same
morphology of NMC located elsewhere, and in any
case of undifferentiated laryngeal carcinoma IHC with
the NUT antibody should be considered. Morphologi-




Figure 1. Pathological and molecular features of laryngeal nuclear protein in testis (NUT) midline carcinoma (NMC). A, Case 1 reveals typi-
cal undifferentiated morphology of NMC, exhibiting sheets of moderate-sized cells with monomorphic round nuclei and distinct nucleoli. The
neutrophilic infiltrate observed in this case is unusual in carcinoma, but seen frequently in NMC (haematoxylin and eosin). B, Diagnostic
NUT immunohistochemistry in case 5 revealing diffuse nuclear staining in a speckled pattern (inset). C, Bromodomain containing 4
(BRD4)–NUT fusion fluorescence in-situ hybridization (FISH) using probes covering NUT (green) and BRD4 (red) genes reveals a reciprocal
fusion at both NUT (ch. 15q14) and BRD4 (ch. 19p13.1) loci (yellow, overlapping probes). The findings are consistent with a BRD4–NUT
fusion in this tumour. D, Case 5 reveals classic NMC morphology with abrupt squamous differentiation (left) and sheets of monomorphic
rounds cells separated by clear spaces (right). The frequent single necrotic cells and mitoses are indicative of the aggressive biology of this
cancer.
© 2016 John Wiley & Sons Ltd, Histopathology, 70, 861–868.
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carcinoma admixed with squamous differentiation,
and where the undifferentiated cells tend to be round
and may mimic a small round blue cell tumour. The
important differential diagnosis of a small round cell
tumour has been pointed out by Bishop and associ-
ates.30,31 Necrosis, including frequent single cell
necrosis and high mitotic rate, are present in NMCs.
Neutrophilic infiltrates are often present, a feature
not seen commonly in other laryngeal carcinomas. A
young age of the patient should also alert the pathol-
ogist. In our review the mean age was 34 years,
which is considerably younger and atypical for con-
ventional laryngeal carcinomas. The patients also
tend to present at an advanced clinical stage, often
stage IV, illustrated for example by case 7, where the
patient at diagnosis was staged T4aN3M1.
The clinical outcome for patients with laryngeal
NMC and for NMC located elsewhere is, in general,
dismal. Chemotherapy or radiation therapy alone for
head and neck NMC has been shown to be inade-
quate, while aggressive initial resection with or with-
out postoperative chemotherapy or radiation has
been reported to carry a significantly enhanced sur-
vival in a series of 48 patients with NMC.23 Neverthe-
less, head and neck NMC has a poor prognosis in
general, and this is the case with laryngeal NMC.
Clinical outcome data were available in six patients
in our series of seven patients,, and here the survival
ranged from 3 to 11 months. A very recent report
has shown very promising clinical response by the
use of bromodomain and extra-terminal (BET) bro-
modomain (BRD) inhibitors. The antitumour activity
of novel oral BET inhibitor (OTX015/MK-8628) was
evaluated in four patients with advanced-stage NMC
and showed impressive and rapid antitumour activity
in NMC. Two of the patients responded rapidly with
tumour regression and a third had meaningful dis-
ease stabilization.32
We conclude that laryngeal NMC is a rarity, but
may be underdiagnosed. It has characteristic morpho-
logical features, and positive immunohistochemical
staining with the NUT antibody is diagnostic. An
increased awareness among pathologists is warranted
due to its aggressive behaviour demanding a different
treatment strategy than conventional poorly differen-
tiated laryngeal carcinomas.
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